Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic

Award Number: R44CA192451
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/03/2015
PERIOD OF PERFORMANCE END DATE: 08/31/2018

Group Awards By:

View Award Description

Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic - DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the most commonly diagnosed cancer and second leading cause of cancer death in American men. The utility of the widely accepted diagnostic test for PCa, the PSA test, has come under severe scrutiny as only 20-30% of men with PCa have levels that fall within the current PSA reference range. Elevated PSA levels are not correlated well with the stage of PCa and a significant number of men are exposed to unnecessary surgery and radiation therapy with concomitant risks and detrimental side effects. Molecular imaging of PCa is an increasingly important component for diagnosis, staging and treatment of the disease. However, the FDA has approved only one diagnostic agent for PCa since 1996, ProstaScint", a mouse monoclonal antibody. While the marker that ProstaScint" recognizes, prostate-specific membrane antigen (PSMA), is ideal as a biomarker, ProstaScint" binds an intracellular epitope, rendering it unable to detect living PCa cells. As a result, diagnostic accuracy of less than 50% has led to poor adoption of this imaging test by oncologists. PSMA, a transmembrane protein, has been described as an ideal biomarker for PCa diagnosis and targeted therapy as it 1) is expressed mainly in PCa with a prevalence of >90%, 2) has high expression levels at all stages of the disease and is upregulated in androgen-insensitive and metastatic disease, 3) is accessible on the cell surface and not shed into the circulation, and 4) is internalized after ligand binding. To address the unmet need for accurate and quantitative imaging of PCa we will advance our novel, proprietary, low molecular weight PSMA inhibitor that selectively delivers an imaging radionuclide to PCa cells. This small molecule inhibitor, CTT1057, binds PSMA irreversibly at an IC50 of less than 1 nM. In addition, CTT1057 and its 18F imaging payload is internalized into PSMA expressing cells in less than 30 minutes. This irreversible binding and rapid internalization makes this molecule unique amongst PSMA inhibitors that are in development and allows for excellent biodistribution and tumor uptake. In addition, we are pursuing the more sensitive and quantitative diagnostic imaging modality of PET (as opposed to SPECT) using a 18F-labeled radiotracer. In this grant we will advance the development of our PET imaging agent CTT1057 by completing the cGMP manufacture and automated radiolabeling of Phase I clinical material in Aim 1. In Aim 2, we will establish a human safety profile as well as visualize PCa lesions and determine optimal imaging parameters and dosimetry in a Phase 0/I clinical trial in PCa patients. PET imaging using our 18F-labeled PSMA inhibitor CTT1057 will allow for rapid and sensitive assessment of proximal and distal manifestations of PCa, something which is currently unavailable.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2016	CANCER TARGETED TECHNOLOGY LLC	14241 NE WOODINVILLE-DUVALL RD. #143	WOODINVILLE	WA	98072	KING	USA	Cancer Detection and Diagnosis Research	000	2	12/17/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	CANCER TARGETED TECHNOLOGY LLC	14241 NE WOODINVILLE-DUVALL RD. #143	WOODINVILLE	WA	98072	KING	USA	Cancer Detection and Diagnosis Research	000	2	2/26/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $923,913 )
2016	2016	CANCER TARGETED TECHNOLOGY LLC	14136 NE WOODINVILLE-DUVALL RD	WOODINVILLE	WA	98072	KING	USA	Cancer Detection and Diagnosis Research	001	2	2/19/2016	NON-COMPETING CONTINUATION	$923,913
2016	2015	CANCER TARGETED TECHNOLOGY LLC	14136 NE WOODINVILLE-DUVALL RD	WOODINVILLE	WA	98072	KING	USA	Cancer Detection and Diagnosis Research	000	1	2/12/2016	NEW	$0
														Subtotal = $923,913

Issue Date FY: 2015 ( Subtotal = $1,076,087 )
2015	2015	CANCER TARGETED TECHNOLOGY LLC	14136 NE WOODINVILLE-DUVALL RD	WOODINVILLE	WA	98072	KING	USA	Cancer Detection and Diagnosis Research	000	1	3/3/2015	NEW	$1,076,087
														Subtotal = $1,076,087

Grand Total All Awards = $2,000,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic

Award Number: R44CA192451

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/03/2015

PERIOD OF PERFORMANCE END DATE: 08/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer